Disorders of secondary peristalsis are associated with the development of esophagitis
Neurogastroenterology & Motility · 2024-12 · 36 (12)
DOI: 10.1111/nmo.14943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 25.10.2024. Verfasst von Tal David Berger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Hepatology & Nutrition, Boston Children's Hospital, Bost…. Hauptthemen laut MEDLINE: Esophagitis, Peristalsis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background Disorders of primary peristalsis are associated with a higher percent time pH
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Hepatology & Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Samuel Nurko, Rachel Rosen
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Berger, T. D., Kung, J., Chalmers, C., Nemec, G., Wen, A., Nurko, S., & Rosen, R. (2024). Disorders of secondary peristalsis are associated with the development of esophagitis. Neurogastroenterology & Motility, 36(12). https://doi.org/10.1111/nmo.14943
Vancouver
Berger TD, Kung J, Chalmers C, Nemec G, Wen A, Nurko S, et al. Disorders of secondary peristalsis are associated with the development of esophagitis. Neurogastroenterology & Motility. 2024;36(12). doi:10.1111/nmo.14943
BibTeX
@article{Berger2024,
author = {Berger, Tal David and Kung, Jasmine and Chalmers, Christopher and Nemec, Grace and Wen, Anna and Nurko, Samuel and Rosen, Rachel},
title = {Disorders of secondary peristalsis are associated with the development of esophagitis},
journal = {Neurogastroenterology & Motility},
year = {2024},
volume = {36},
number = {12},
doi = {10.1111/nmo.14943}
}
EUVIMED